Actinium Pharmaceuticals Trickling Down Through 2023: Are They Flying Under The Radar?

Abstract blue neon stadium background illuminated with lamps on ground. Science, product and sports technology background

gleitfrosch/iStock via Getty Images

Topline Summary

Actinium Pharmaceuticals (NYSE:ATNM) has had a bumpy year, with a lot of hype headed into 2023 only to have a big setback in March, and a slow descent ever since. Lack of clarity on data

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *